FindTrial
Sign In

Effect of Bupropion on second generation antipsychotic induced weight gain and Melanocyte stimulating hormone (MSH) in patients with schizophrenia.

Effect of Bupropion on second generation antipsychotic induced weight gain and Melanocyte stimulating hormone (MSH) in patients with schizophrenia and its relationship with cognitive symptoms- An open label study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/057007
Enrollment
50
Registered
2023-08-28
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F209- Schizophrenia, unspecified

Interventions

Intervention1: Bupropion therapy: Tablet Bupropion XL 300mg/day orally for 8 weeks in schizophrenia patients along with second generation antipsychotics Control Intervention1: NIL: NIL

Sponsors

Central Institute of Psychiatry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: In-patients satisfying the ICD-11 DCR criteria for schizophrenia. First episode schizophrenia (2years) Age 18-50yrs of both sexes. BMI greater than or equal to 25 kg/m2 CDSS score Those who give written informed consent for participating in the study.

Exclusion criteria

Exclusion criteria: Any other drug(except for Antipsychotics) that can cause weight gain. Patients on 1st generation antipsychotics and or on 1st generation depot antipsychotics. Co-morbid endocrine and/or cardiovascular conditions. Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine and caffeine. Known hypersensitivity to Tab. Bupropion or any of its components. Deranged liver function test ( ALT greater than/equal to 180 IU/L and/or AST greater than/equal to 140 IU/L) Significant current/past medical or neurological illness including severe hepatic disease and history of severe head injury. Patients currently receiving ECT. Treatment resistant schizophrenia patients or patients on clozapine. History of suicidality (intent/attempt) QTc interval greater than/equal to 450ms in males and greater than/equal to 470ms in females on Electrocardiogram (ECG). Pregnancy.

Design outcomes

Primary

MeasureTime frame
Effectiveness of tab Bupropion XL 300mg/day on metabolic profile in patients of Schizophrenia on second generation anti psychotics assessed by changes in BMI lipid profiles fasting blood glucose & waist circumference and its relationship with BPRS PANSS CGI SCH CDSS SANS MoCA scales.Timepoint: Baseline 4 weeks 8 weeks—

Secondary

MeasureTime frame
Changes in levels of Melanocyte Stimulating Hormone in patients receiving Tab Bupropion XL 300mg/day.Timepoint: Baseline 4 weeks 8weeks—

Countries

India

Contacts

Public ContactDr Surendra Paliwal

Central Institute of Psychiatry

itsme.paliwal@gmail.com8005940887

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026